Table 1 Clinical characteristics of the 227 patients with pyogenic liver abscess patients with diabetes or without diabetes presented at admission
Values | Median (range)/n (percentage) | Diabetes mellitus | Non-diabetes mellitus | p value |
|---|---|---|---|---|
n | 227 | 61 (26.87%) | 166 (73.13%) | Â |
Age (years) | 56 (11–84) | 57 (22–84) | 56 (11–84) | 0.837 |
Gender (male) | 135 (59.47%) | 39 (63.93%) | 96 (57.83%) | 0.406 |
Underlying conditions | ||||
 Smoking | 66 (29.07%) | 16 (26.23%) | 50 (30.12%) | 0.567 |
 Drinking | 43 (18.94%) | 33 (19.88%) | 10 (16.39%) | 0.552 |
 Hypertension | 43 (18.94%) | 31 (50.82%) | 12 (7.23%) | < 0.001 |
 Cirrhosis | 8 (3.52%) | 2 (3.28%) | 6 (3.61%) | 0.902 |
Body temperature at admission (°C) | ||||
 35.5 °C~ 37.3 °C | 138 (60.79%) | 42 (68.85%) | 96 (57.83%) | 0.319 |
 37.4 °C~ 39 °C | 79 (34.80%) | 17 (27.87%) | 62 (37.35%) | |
  > 39.1 °C | 10 (4.41%) | 2 (3.28%) | 8 (4.82%) | |
Time for temperature normalization (days) | 6.39 (0–40) | 6.05 (0–24) | 6.51 (0–40) | 0.593 |
Laboratory tests | ||||
 WBC > 10 × 109/L | 119 (52.42%) | 23 (37.70%) | 96 (57.83%) | 0.007 |
 WBC < 3.5 × 109/L | 4 (1.76%) | 3 (4.92%) | 1 (0.60%) | 0.105 |
 ALT > 40 U/L | 108 (47.58%) | 25 (40.98%) | 83 (50.00%) | 0.228 |
 AST > 40 U/L | 67 (29.52%) | 15 (24.59%) | 52 (31.33%) | 0.324 |
 ALB < 35 g/L | 169 (74.45%) | 45 (73.77%) | 124 (74.70%) | 0.887 |
 TBIL > 17 μmol/L | 96 (42.29%) | 31 (50.82%) | 65 (39.16%) | 0.115 |
 PT > 17 s | 20 (8.81%) | 6 (9.84%) | 14 (8.43%) | 0.741 |
 APTT > 45 s | 26 (11.45%) | 7 (11.48%) | 19 (11.45%) | 0.995 |
 BUN > 7.2 mmol/L | 16 (7.27%) | 7 (11.67%) | 9 (5.63%) | 0.213 |
 Cr > 97 μmol/L | 30 (13.64%) | 7 (11.67%) | 23 (14.37%) | 0.602 |
Abscess number | ||||
 Solitary abscess | 172 (75.77%) | 47 (77.05%) | 125 (75.30%) | 0.785 |
 Multiple abscess | 55 (24.23%) | 14 (22.95%) | 41 (24.70%) | |
Maximal diameter of abscess | ||||
  ≤ 5 cm | 75 (33.04%) | 24 (39.34%) | 51 (30.72%) | 0.116 |
 5~10 cm | 132 (58.15%) | 34 (55.74%) | 98 (59.04%) | |
  > 10 cm | 20 (8.81%) | 3 (4.92%) | 17 (10.24%) | |
Abscess site | ||||
 Left lobe | 34 (14.98%) | 6 (9.84%) | 28 (16.87%) | 0.289 |
 Right lobe | 137 (60.35%) | 43 (70.49%) | 94 (56.63%) | |
 Both left and right | 41 (18.06%) | 9 (14.75%) | 32 (19.28%) | |
 Other sites | 15 (6.61%) | 3 (4.92%) | 12 (7.23%) | |
Gas forming | 45 (19.82%) | 15 (24.59%) | 30 (18.07%) | 0.275 |
Medicine use | ||||
 Steroid hormone | 57 (25.11%) | 21 (34.43%) | 36 (21.69%) | 0.050 |
Hepatoprotective drugs | 126 (55.51%) | 36 (59.02%) | 90 (54.22%) | 0.519 |
Immune response enhancer | 42 (18.50%) | 24 (39.34%) | 18 (10.84%) | < 0.001 |